{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:43:15Z","timestamp":1791286995414,"version":"4.1.0"},"reference-count":56,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Mast cell activation syndrome (MCAS) is an immune disease with an estimated prevalence of 17%. Mast cell chemical mediators lead to heterogeneous multisystemic inflammatory and allergic manifestations. This syndrome is associated with various neurologic and psychiatric disorders, including headache, dysautonomia, depression, generalized anxiety disorder, and many others. Although MCAS is common, it is rarely recognized, and thus, patients can suffer for decades. The syndrome is caused by aberrant mast cell reactivity due to the mutation of the controller gene. A case series is presented herein including eight patients with significant neuropsychiatric disorders that were often refractory to standard medical therapeutics. Five patients had depression, five had generalized anxiety disorder, and four had panic disorder. Other psychiatric disorders included attention-deficit hyperactivity disorder, obsessive compulsive disorder, phobias, and bipolar disorder. All eight patients were subsequently diagnosed with mast cell activation syndrome; six had comorbid autonomic disorders, the most common being postural orthostatic tachycardia syndrome; and four had hypermobile Ehlers-Danlos syndrome. All patients experienced significant improvements regarding neuropsychiatric and multisystemic symptoms after mast-cell-directed therapy. In neuropsychiatric patients who have systemic symptoms and syndromes, it is important to consider the presence of an underlying or comorbid MCAS.<\/jats:p>","DOI":"10.3390\/jpm13111562","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T11:16:27Z","timestamp":1698750987000},"page":"1562","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Neuropsychiatric Manifestations of Mast Cell Activation Syndrome and Response to Mast-Cell-Directed Treatment: A Case Series"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6484-1691","authenticated-orcid":false,"given":"Leonard B.","family":"Weinstock","sequence":"first","affiliation":[{"name":"Independent Researcher, Specialists in Gastroenterology, St. Louis, MO 63141, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee M.","family":"Nelson","sequence":"additional","affiliation":[{"name":"Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY 14203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3982-2031","authenticated-orcid":false,"given":"Svetlana","family":"Blitshteyn","sequence":"additional","affiliation":[{"name":"Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY 14203, USA"},{"name":"Dysautonomia Clinic, Williamsville, NY 14221, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3109\/07853890.2016.1161231","article-title":"Often seen, rarely recognized: Mast cell activation disease\u2014A guide to diagnosis and therapeutic options","volume":"48","author":"Afrin","year":"2016","journal-title":"Ann. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.amjms.2016.12.013","article-title":"Characterization of Mast Cell Activation Syndrome","volume":"353","author":"Afrin","year":"2017","journal-title":"Am. J. Med. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.iac.2018.04.002","article-title":"Nonclonal Mast Cell Activation Syndrome: A Growing Body of Evidence","volume":"38","author":"Hamilton","year":"2018","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bbi.2015.07.002","article-title":"Mast cell activation disease: An underappreciated cause of neurologic and psychiatric symptoms and diseases","volume":"50","author":"Afrin","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Molderings, G.J., Haenisch, B., Bogdanow, M., Fimmers, R., and N\u00f6then, M.M. (2013). Familial Occurrence of Systemic Mast Cell Activation Disease. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0076241"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1515\/dx-2020-0005","article-title":"Diagnosis of mast cell activation syndrome: A global \u201cconsensus-2\u201d","volume":"8","author":"Afrin","year":"2020","journal-title":"Diagnosis"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/00365520701245744","article-title":"Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder","volume":"42","author":"Molderings","year":"2007","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Shelestak, J., Singhal, N., Frankle, L., Tomor, R., Sternbach, S., McDonough, J., Freeman, E., and Clements, R. (2020). Increased blood-brain barrier hyperpermeability coincides with mast cell activation early under cuprizone administration. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0234001"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s10620-020-06264-9","article-title":"Mast Cell Activation Syndrome: A Primer for the Gastroenterologist","volume":"66","author":"Weinstock","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.critrevonc.2014.09.001","article-title":"The genetic basis of mast cell activation disease\u2014Looking through a glass darkly","volume":"93","author":"Molderings","year":"2015","journal-title":"Crit. Rev. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/s41395-018-0215-4","article-title":"Postural Tachycardia Syndrome (POTS) and the GI Tract: A Primer for the Gastroenterologist","volume":"113","author":"DiBaise","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ajmg.c.31538","article-title":"Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome Type III and Ehlers-Danlos syndrome hypermobility type): Clinical description and natural history","volume":"175","author":"Tinkle","year":"2017","journal-title":"Am. J. Med. Genet. Part C Semin. Med. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1007\/s10620-023-07921-5","article-title":"Cluster-Analytic Identification of Clinically Meaningful Subtypes in MCAS: The Relevance of Heat and Cold","volume":"68","author":"Molderings","year":"2023","journal-title":"Dig. Dis. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00210-016-1247-1","article-title":"Pharmacological treatment options for mast cell activation disease","volume":"389","author":"Molderings","year":"2016","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s13071-017-2243-0","article-title":"Interaction of primary mast cells with Borrelia burgdorferi (sensu stricto): Role in transmission and dissemination in C57BL\/6 mice","volume":"10","author":"Bernard","year":"2017","journal-title":"Parasites Vectors"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.33425\/2639-944X.1170","article-title":"Small Intestinal Bacterial Overgrowth is Common in Mast Cell Activation Syndrome","volume":"4","author":"Weinstock","year":"2020","journal-title":"J. Med. Clin. Res. Rev."},{"key":"ref_17","first-page":"763","article-title":"Impact of mold on mast cell-cytokine immune response","volume":"32","author":"Kritas","year":"2018","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/toxsci\/71.2.137","article-title":"Chemical Allergy: Considerations for the Practical Application of Cytokine Profiling","volume":"71","author":"Dearman","year":"2003","journal-title":"Toxicol. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/(SICI)1097-4636(19980315)39:4<560::AID-JBM9>3.0.CO;2-H","article-title":"Metal ion-induced toxic histamine release from human basophils and mast cells","volume":"39","author":"Schedle","year":"1998","journal-title":"J. Biomed. Mater. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jad.2016.08.029","article-title":"Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants","volume":"208","author":"Mischoulon","year":"2017","journal-title":"J. Affect. Disord."},{"key":"ref_21","first-page":"bcr-2017","article-title":"Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment","volume":"2018","author":"Weinstock","year":"2018","journal-title":"BMJ Case Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00210-022-02282-8","article-title":"Efficacy and toxicity of hydroxyurea in mast cell activation syndrome patients refractory to standard medical therapy: Retrospective case series","volume":"395","author":"Weinstock","year":"2022","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_23","first-page":"92","article-title":"Tinnitus in Mast Cell Activation Syndrome: A Prospective Survey of 114 Patients","volume":"4","author":"Weinstock","year":"2021","journal-title":"J. Otolaryngol. Neurotol. Res."},{"key":"ref_24","first-page":"401","article-title":"Restless legs syndrome is associated with mast cell activation syndrome","volume":"16","author":"Weinstock","year":"2020","journal-title":"Sleep Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1182\/blood-2013-04-498105","article-title":"Mast cell activation contributes to sickle cell pathobiology and pain in mice","volume":"122","author":"Vincent","year":"2013","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.neubiorev.2017.05.001","article-title":"Mast cells in neuroinflammation and brain disorders","volume":"79","author":"Hendriksen","year":"2017","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"200","DOI":"10.12659\/MSMBR.893093","article-title":"Mast Cells and Neuroinflammation","volume":"20","author":"Qian","year":"2014","journal-title":"Med. Sci. Monit. Basic Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2500\/aap.2021.42.210022","article-title":"The relationship between mast cell activation syndrome, postural tachycardia syndrome, and Ehlers-Danlos syndrome","volume":"42","author":"Wang","year":"2021","journal-title":"Allergy Asthma Proc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jaut.2018.03.001","article-title":"Mechanisms of neuropsychiatric lupus: The relative roles of the blood-cerebrospinal fluid barrier versus blood-brain barrier","volume":"91","author":"Gelb","year":"2018","journal-title":"J. Autoimmun."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Moura, D.S., Sultan, S., Georgin-Lavialle, S., Pillet, N., Montestruc, F., Gineste, P., Barete, S., Damaj, G., Moussy, A., and Lortholary, O. (2011). Depression in Patients with Mastocytosis: Prevalence, Features and Effects of Masitinib Therapy. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0026375"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.trsl.2016.03.013","article-title":"Mastocytosis in adulthood and neuropsychiatric disorders","volume":"174","author":"Gaillard","year":"2016","journal-title":"Transl. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3389\/fnins.2017.00703","article-title":"Mast Cell Activation in Brain Injury, Stress, and Post-traumatic Stress Disorder and Alzheimer\u2019s Disease Pathogenesis","volume":"11","author":"Kempuraj","year":"2017","journal-title":"Front. Neurosci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.anai.2021.06.014","article-title":"Coping, social support, and anxiety in people with mast cell disorders","volume":"127","author":"Carroll","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1177\/13591053211014583","article-title":"Depression, psychosocial correlates, and psychosocial resources in individuals with mast cell activation syndrome","volume":"27","author":"SantaBarbara","year":"2021","journal-title":"J. Health Psychol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13023-021-01747-y","article-title":"Neuropsychiatric, cognitive and sexual impairment in mastocytosis patients","volume":"16","author":"Jendoubi","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0162-3109(99)00046-6","article-title":"Inhibition of mouse mast cell proliferation and proinflammatory mediator release by benzodiazepines","volume":"43","author":"Bidri","year":"1999","journal-title":"Immunopharmacology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0091-3057(02)00708-6","article-title":"Experimental anxiety induced by histaminergics in mast cell-deficient and congenitally normal mice","volume":"72","author":"Ikarashi","year":"2002","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e1197","DOI":"10.1038\/tp.2017.137","article-title":"Neuroimaging evidence of brain abnormalities in mastocytosis","volume":"7","author":"Boddaert","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41398-018-0143-5","article-title":"White matter abnormalities are also repeatedly present in patients with systemic mast cell activation syndrome","volume":"8","author":"Haenisch","year":"2018","journal-title":"Transl. Psychiatry"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/978-1-4419-8056-4_10","article-title":"Histamine in neurotransmission and brain diseases","volume":"709","author":"Nuutinen","year":"2010","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"106989","DOI":"10.1016\/j.ympev.2020.106989","article-title":"Evolutionary history of histamine receptors: Early vertebrate origin and expansion of the H3-H4 subtypes","volume":"154","author":"Ravhe","year":"2020","journal-title":"Mol. Phylogenet. Evol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.3389\/fimmu.2018.01873","article-title":"The Role of Histamine and Histamine Receptors in Mast Cell-Mediated Allergy and Inflammation: The Hunt for New Therapeutic Targets","volume":"9","author":"Thangam","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1755-5949.2010.00212.x","article-title":"Histamine Pharmacology and New CNS Drug Targets","volume":"17","author":"Tiligada","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"ref_44","unstructured":"Rich, R.R., Fleisher, T.A., Shearer, W.T., Schroeder, H.W., Frew, A.J., and Weyand, C.M. (2008). Clinical Immunology, Mosby. [3rd ed.]. Chapter 89."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Cheng, L., Liu, J., and Chen, Z. (2021). The Histaminergic System in Neuropsychiatric Disorders. Biomolecules, 11.","DOI":"10.3390\/biom11091345"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/ijnp\/pyx018","article-title":"Histamine Receptors in the Cross-Talk between Periphery and Brain","volume":"20","author":"Lindskog","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"9524075","DOI":"10.1155\/2018\/9524075","article-title":"Role of Histamine in Modulating the Immune Response and Inflammation","volume":"2018","author":"Branco","year":"2018","journal-title":"Mediat. Inflamm."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.amjms.2019.03.005","article-title":"Recognition and Management of Medication Excipient Reactivity in Patients with Mast Cell Activation Syndrome","volume":"357","author":"Schofield","year":"2019","journal-title":"Am. J. Med. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.lfs.2013.01.010","article-title":"Investigation into mechanisms mediating the inhibitory effect of 1,4-benzodiazepines on mast cells by gene expression profiling","volume":"92","author":"Haenisch","year":"2013","journal-title":"Life Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/7854_2021_262","article-title":"Histamine Neuroimaging in Stress-Related Disorders","volume":"Volume 59","author":"Fukudo","year":"2022","journal-title":"The Functional Roles of Histamine Receptors"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/B978-0-12-820107-7.00023-9","article-title":"Histamine receptors, agonists, and antagonists in health and disease","volume":"180","author":"Panula","year":"2021","journal-title":"Handb. Clin. Neurol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12974-018-1068-x","article-title":"Histamine upregulates the expression of histamine receptors and increases the neuroprotective effect of astrocytes","volume":"15","author":"Xu","year":"2018","journal-title":"J. Neuroinflamm."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0140-6736(16)31403-9","article-title":"Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: A randomised, placebo-controlled, phase 3 study","volume":"389","author":"Lortholary","year":"2017","journal-title":"Lancet"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e021002","DOI":"10.1161\/JAHA.121.021002","article-title":"Mast Cell Activation Disorder and Postural Orthostatic Tachycardia Syndrome: A Clinical Association","volume":"10","author":"Kohno","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.anai.2021.10.006","article-title":"Mast cell disorders are associated with decreased cerebral blood flow and small fiber neuropathy","volume":"128","author":"Novak","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Blitshteyn, S. (2023). Dysautonomia, Hypermobility Spectrum Disorders and Mast Cell Activation Syndrome as Migraine Comorbidities. Curr. Neurol. Neurosci. Rep., ahead of print.","DOI":"10.1007\/s11910-023-01307-w"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/11\/1562\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:14:42Z","timestamp":1760130882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/13\/11\/1562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,31]]},"references-count":56,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["jpm13111562"],"URL":"https:\/\/doi.org\/10.3390\/jpm13111562","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,31]]}}}